2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, van Oordt C, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clinical Cancer Research 2022, 28: 2020-2029. PMID: 35165101, PMCID: PMC9365353, DOI: 10.1158/1078-0432.ccr-21-3656.Peer-Reviewed Original ResearchConceptsAdvanced solid tumorsOpen-label phase I/II trialSolid tumorsPhase I/II trialPhase I/II clinical trialsBasis of tolerabilityPhase II doseBreast cancer subsetsAntibody-drug conjugatesProtease-cleavable linkerEligible patientsPosttreatment biopsiesPrior therapyStable diseaseII trialPartial responseSafety profileTumor regressionClinical trialsPrevalent subtypeCancer subsetsClinical activityMetastatic cancerBreast cancerMedian number
2010
A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer.
Harb W, Conley B, LoRusso P, Sausville E, Heath E, Chandana S, Hamm M, Carter J, Perez W, Messmann R. A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer. Journal Of Clinical Oncology 2010, 28: 3088-3088. DOI: 10.1200/jco.2010.28.15_suppl.3088.Peer-Reviewed Original Research
2001
Analysis of skeletal-related events in breast cancer and response to therapy
LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Seminars In Oncology 2001, 28: 22-27. PMID: 11544572, DOI: 10.1016/s0093-7754(01)90228-3.Peer-Reviewed Original ResearchConceptsBone metastasesSkeletal morbiditySkeletal complicationsSkeletal related eventsTreatment of choiceBone painIntravenous pamidronateBisphosphonate treatmentSignificant morbidityCancer patientsPotent bisphosphonateStandard treatmentBone resorptionSurrogate markerClinical trialsCommon siteMetastatic cancerBreast cancerMorbidityMetastasisPatientsLife measurementsTherapyComplicationsPamidronate